SPX 6,124.35 ▲ 0.47%DJI 44,210.18 ▼ 0.12%CCMP 19,875.02 ▲ 0.72%SX5E 5,231.77 ▲ 0.24%UKX 8,402.11 ▼ 0.22%NKY 39,870.50 ▲ 0.78%EURUSD 1.0842 ▼ 0.19%USGG10YR 4.31 ▲ 0.94%CL1 71.82 ▼ 0.88%XAU 2,685.40 ▲ 0.42%XBT 97,250.00 ▲ 1.93%SPX 6,124.35 ▲ 0.47%DJI 44,210.18 ▼ 0.12%CCMP 19,875.02 ▲ 0.72%SX5E 5,231.77 ▲ 0.24%UKX 8,402.11 ▼ 0.22%NKY 39,870.50 ▲ 0.78%EURUSD 1.0842 ▼ 0.19%USGG10YR 4.31 ▲ 0.94%CL1 71.82 ▼ 0.88%XAU 2,685.40 ▲ 0.42%XBT 97,250.00 ▲ 1.93%
 

← Persons Index

Robert Duggan
Rank #423 · Healthcare

Robert Duggan

Pharmaceuticals · United States

Net worth$8.6B
Today−$306M
7 days−$2.7M
30 days−$3.6B

Net worth, last 30 days

Low $8.6BHigh $13.8B

Biography

In 2020, Robert Duggan invested $63 million in Nasdaq-listed Summit Therapeutics and became its Co-CEO, leading the biotech in developing targeted oncology therapies for difficult diagnoses.

Pharmacyclics' cancer drug Imbruvica made Duggan a billionaire in 2013 and paved the way for the company's $21 billion sale to AbbVie in 2015.

Duggan, whose son died from brain cancer, became passionate about Pharmacyclic's cancer fighting drugs and first invested in 2004.

His enthusiasm for investing began four decades earlier in a corporate finance class he took at the University of California at Santa Barbara.

He married Summit co-CEO Maky Zanganeh, who is also a billionaire, in 2024.

Duggan also sits on the board of Pulse Biosciences, of which he is the largest individual shareholder.

Did you know

Duggan is a big donor to the Church of Scientology, of which he is a member; he says he's given the church nearly $360 million over his lifetime.

Duggan enjoys surfing in his spare time.

Holdings

CompanyTickerSharesValue
AbbVie Inc.ABBV-US100$28K
Akeso Inc9926-HK2,890,000$176M
AlphabetGOOGL-US5,000$1.4M
Boston ScientificBSX-US100$4K
Edwards LifesciencesEW-US100$10K
Eli Lilly & Co.LLY-US200$270K
Google Inc. (Cl C)GOOG-US120,600$33M
Intel Corp.INTC-US900$50K
Intuitive SurgicalISRG-US10,400$4.2M
Johnson & JohnsonJNJ-US1,000$267K
JPMorgan Chase & Co.JPM-US100$32K
Mereo BiopharmaMREO-US842,400$232K
MicrosoftMSFT-US200$100K
NvidiaNVDA-US230$34K
PalantirPLTR-US100$15K
Protagonist TherapeuticsPTGX-US100$12K
Pulse BioSciencesPLSE-US49,450,000$2.2B
Pulse BioSciencesPLSE-US33,000$1.5M
Summit TherapeuticsSMMT-US6,000$63K
Summit TherapeuticsSMMT-US573,883,000$6.1B
Summit TherapeuticsSMMT-US4,795,000$51M
Summit TherapeuticsSMMT-US10,700$113K
X-EnergyXE-US924,500$9M
Private assets & other$516M

Public holdings ≈ $8.5B. Holdings may include options and overlap between rows.